Deferred Revenue - Narrative (Details)											1 Months Ended	12 Months Ended			15 Months Ended	23 Months Ended
	Sep. 30, 2019 shares	Sep. 19, 2018 USD ($)	Sep. 05, 2018 shares	May 28, 2016 USD ($)	Dec. 23, 2015 USD ($)	Oct. 02, 2015 USD ($)	Sep. 22, 2015 USD ($)	Jul. 20, 2015 USD ($)	Sep. 17, 2014 USD ($) shares	Dec. 17, 2013 USD ($) shares	Sep. 30, 2018 shares	Mar. 31, 2021 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) shares	Dec. 31, 2019 USD ($)	Mar. 31, 2020 USD ($)	Apr. 17, 2018 USD ($)
Disaggregation of Revenue [Line Items]
Proceeds from funding agreement				$ 266,500	$ 715,500	$ 618,000	$ 1,600,000	$ 250,000	$ 500,000	$ 250,000
Interest in asset				0.35533%	0.954%	0.824%	2.1333%	0.50%	1.00%	0.50%
Number of shares issuable term							60 days		60 days	60 days
Number of shares issuable (in shares) | shares									62,500	31,250
Recognized as revenue													$ 2,694,000	$ 683,000
Issuance of common stock for cash, net of issuance costs (in shares) | shares	11,788
Grants receivable																	$ 7,400,000
Total Revenue													40,519,800	13,982,177
Deferred revenue, period increase (decrease)													2,400,000	1,000,000
Deferred revenue as a current liability													918,272	$ 1,212,149	$ 918,272
Common Stock
Disaggregation of Revenue [Line Items]
Issuance of common stock for cash, net of issuance costs (in shares) | shares														1,051,034
Valour | Common Stock
Disaggregation of Revenue [Line Items]
Issuance of common stock for cash, net of issuance costs (in shares) | shares			160,000								160,000
Within 2.5 Years
Disaggregation of Revenue [Line Items]
Buyback term on ownership percentage							2 years 6 months
Buyback rate							2
After 2.5 Years
Disaggregation of Revenue [Line Items]
Buyback term on ownership percentage							2 years 6 months
Buyback rate							3.5
Research and Development Arrangement December 17, 2013
Disaggregation of Revenue [Line Items]
Recognized as revenue													115,900	$ 58,000
Research and Development Arrangement September 17, 2014
Disaggregation of Revenue [Line Items]
Recognized as revenue													313,700	156,900
Research and Development Arrangement July 20, 2015
Disaggregation of Revenue [Line Items]
Recognized as revenue													214,300	35,700
Research And Development Arrangement September 19, 2018
Disaggregation of Revenue [Line Items]
Total Revenue													234,000
Grant
Disaggregation of Revenue [Line Items]
Total Revenue													$ 2,000,000	$ 432,000
Grant | Scenario, Forecast
Disaggregation of Revenue [Line Items]
Total Revenue												$ 1,800,000				$ 5,600,000
Biomedical Advanced Research and Development Authority (BARDA)
Disaggregation of Revenue [Line Items]
Proceeds from funding agreement															$ 3,000,000
Biomedical Advanced Research and Development Authority (BARDA) | Plan
Disaggregation of Revenue [Line Items]
Proceeds from funding agreement		$ 4,600,000